8-K: Envoy Medical Stockholders Approve Warrant Issuance

Envoy Medical, Inc. stockholders approved the issuance of warrants and underlying Class A Common Stock to comply with Nasdaq listing rules at a Special Meeting held on November 26, 2025.

Summary

• A Special Meeting of Stockholders was held by Envoy Medical, Inc. on November 26, 2025.
• Stockholders approved the Issuance Proposal, which involved the issuance of warrants to purchase Class A Common Stock and the issuance of Class A Common Stock underlying these warrants.
• This approval was necessary to comply with Nasdaq Listing Rule 5635(d) and relates to a securities purchase agreement dated September 22, 2025, and an engagement letter dated September 17, 2025, with H.C. Wainwright & Co., LLC.
• The votes for the Issuance Proposal were: 13,599,174 'For', 243,009 'Withheld', and 5,700 'Broker Non-Votes'.
• Stockholders also approved an administrative Adjournment Proposal, which would have allowed for adjourning the meeting to gather more votes or ensure a quorum, but this authority was not utilized.
• The votes for the Adjournment Proposal were: 13,345,775 'For', 247,335 'Withheld', and 6,064 'Broker Non-Votes'.

Sentiment

Score: 7

Explanation: The successful approval of a critical corporate governance proposal, necessary for Nasdaq compliance and likely facilitating financing, is a positive development for the company.

Positives

• Stockholders approved the Issuance Proposal, ensuring compliance with Nasdaq Listing Rule 5635(d).
• The approval facilitates the execution of a securities purchase agreement and an engagement letter, which are likely related to financing activities.

Future Outlook

The approval of the Issuance Proposal enables Envoy Medical to proceed with the terms of its securities purchase agreement and engagement letter, which are likely related to future capital raising or financial commitments, ensuring continued compliance with Nasdaq listing requirements.

Management Comments

• Brent T. Lucas, Chief Executive Officer, signed the report on behalf of Envoy Medical, Inc.

Industry Context

This announcement reflects a standard corporate governance action for a publicly traded company, ensuring compliance with stock exchange rules. Such approvals are often a prerequisite for or a follow-up to financing activities, common in the medical device or biotechnology sector for funding research, development, or commercialization efforts.

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of warrant issuance could lead to potential dilution of existing shares if warrants are exercised, but it also ensures the company's ability to raise capital and maintain Nasdaq compliance.
• Company: The company can proceed with its financing plans and maintain good standing with Nasdaq.

Next Steps

• Proceed with the issuance of warrants and Class A Common Stock as approved by the stockholders, in accordance with the securities purchase agreement and engagement letter.

Key Dates

Recommendation

The approval of the warrant issuance is a necessary corporate action that ensures Nasdaq compliance and facilitates potential financing. While positive for governance, the potential for future dilution from warrant exercise warrants a 'hold' stance until the full terms and impact of the associated capital raise are clearer and integrated into the company's financial outlook.

Keywords

Envoy Medical, COCH, Warrants, Stockholders Meeting, Nasdaq Compliance, Stock Issuance, Securities Purchase Agreement, Corporate Governance